Cytokinetics (CYTK) Net Cash Flow (2010 - 2026)

Cytokinetics (CYTK) has reported Net Cash Flow for 17 consecutive years, with $7.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow rose 137.13% year-over-year to $7.8 million; the TTM figure through Mar 2026 stood at $59.8 million (up 229.4% YoY), while the FY2025 annual figure was $31.1 million, up 269.37% from the prior year.
• Net Cash Flow rose to $7.8 million in Q1 2026 per CYTK's latest filing, from -$103.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $152.0 million in Q3 2025 and bottomed at -$143.1 million in Q3 2024.
• Historically, Net Cash Flow has averaged $1.3 million across 5 years, with a median of $6.9 million in 2024.
• Annual changes were most pronounced in 2023 — Net Cash Flow surged 1207.47% — and 2024, when it slumped 560.92%.
• Cytokinetics' Net Cash Flow stood at -$39.1 million in 2022, then soared by 134.19% to $13.4 million in 2023, then jumped by 257.08% to $47.7 million in 2024, then slumped by 316.31% to -$103.1 million in 2025, then jumped by 107.53% to $7.8 million in 2026.
• Business Quant data shows CYTK's Net Cash Flow at $7.8 million in Q1 2026, -$103.1 million in Q4 2025, and $152.0 million in Q3 2025.